Emerging studies suggest this peptide, a dual stimulator targeting both incretin and GIP , may offer a significant advancement for weight treatment. Initial human investigations have indicated substantial losses in visceral mass , potentially outperforming other body composition medications . Nevertheless , additional assessment is required to thor